R. Voigtmann

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Dirk Strumberg, Heike Richly, Ralf A. Hilger et al. · Journal of Clinical Oncology · 2004 · 871 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986

Claus Henning Köhne, Eric Van Cutsem, J. Wils et al. · Journal of Clinical Oncology · 2005 · 329 citations

Medicine, Oncology, Pharmacotherapy +16

Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952

C-H Köhne, J. Wils, M. Lorenz et al. · Journal of Clinical Oncology · 2003 · 160 citations

Medicine, Oncology, Pharmacology +14

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

Heike Richly, Bernhard F. Henning, P. Kupsch et al. · Annals of Oncology · 2006 · 142 citations · Full text

Medicine, Oncology, Pharmacology +11

Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.

W Scheef, Klein Ho, N Brock et al. · PubMed · 1979 · 119 citations

Pharmacy, Pharmacology, Pharmacotherapy +15